Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

Research output: Contribution to journalReview articleAcademicpeer-review

94 Citations (Scopus)
277 Downloads (Pure)

Abstract

BACKGROUND: P53, EGFR and HER-2/neu are the most frequently studied molecular biological parameters in epithelial ovarian cancer, but their prognostic impact is still unequivocal. We performed a meta-analysis to more precisely estimate their prognostic significance.

METHODS: Published studies that investigated the association between p53, EGFR and HER-2/neu status and survival were identified. Meta-analysis was performed using a DerSimonian-Laird model. Publication bias was investigated using funnel plots and sources of heterogeneity were identified using meta-regression analysis.

RESULTS: A total of 62 studies were included for p53, 15 for EGFR and 20 for HER-2/neu. P53, EGFR and HER-2/neu status had a modest effect on overall survival (pooled HR 1.47, 95% CI 1.33-1.61 for p53; HR 1.65, 95% CI 1.25-2.19 for EGFR and HR 1.67, 95% CI 1.34-2.08 for HER-2/neu). Meta-regression analysis for p53 showed that FIGO stage distribution influenced study outcome. For EGFR and HER-2/neu, considerable publication bias was present.

CONCLUSIONS: Although p53, EGFR and HER-2/neu status modestly influences survival, these markers are, by themselves, unlikely to be useful as prognostic markers in clinical practice. Our study highlights the need for well-defined, prospective clinical trials and more complete reporting of results of prognostic factor studies. British Journal of Cancer ( 2009) 101, 149-159. doi: 10.1038/sj.bjc.6605112 www.bjcancer.com Published online 9 June 2009 (C) 2009 Cancer Research UK

Original languageEnglish
Pages (from-to)149-159
Number of pages11
JournalBritish Jounal of Cancer
Volume101
Issue number1
DOIs
Publication statusPublished - 30-Jun-2009

Keywords

  • p53
  • EGFR
  • HER-2/neu
  • ovarian cancer
  • meta-analysis
  • EPIDERMAL-GROWTH-FACTOR
  • GYNECOLOGIC-ONCOLOGY-GROUP
  • FACTOR RECEPTOR EXPRESSION
  • PLATINUM-BASED CHEMOTHERAPY
  • TUMOR-SUPPRESSOR GENE
  • PROTEIN EXPRESSION
  • MULTIVARIATE-ANALYSIS
  • SIGNALING PATHWAY
  • POOR-PROGNOSIS
  • EARLY-STAGE

Cite this